Nabi Biopharmaceuticals has announced that it has been granted U.S. Patent No. 6,936,258 entitled "Staphylococcus Antigen and Vaccine" by the U.S. Patent and Trademark Office for the composition of a str
Third Wave Technologies has announced that it has filed two patent suits in federal court in Madison, Wis. The company last Friday filed suit against Digene Corp., seeking a court ruling supportin
Ichor Medical Systems today announced that it has been issued a patent that protects vital elements of the company's technology. U.S. Patent Number 6,912,417 entitled, "Method and Apparatus fo
Domantis Limited, the human Domain Antibody Therapeutics company, has successfully opposed European patent number EP0656946, leading to a major amendment of the main claim in the patent and a signifi
A CSIRO innovation for determining gene function quickly and with virtually 100 per cent efficiency has been granted a US patent clarifying its leadership position in the international gene silencing are
Generex Biotechnology Corporation today announced that it has been granted a patent by the Australian Patent Office titled "Mixed Micellar Pharmaceutical Delivery System and Method of Preparation."
Stressgen Biotechnologies announced today that the U.S. Patent and Trademark Office granted Patent Number 6,921,534 covering fusion protein compositions comprised of a hepatitis B virus (HBV) antige
Generex Biotechnology Corporation has announced that it has been granted a patent by the Canadian Intellectual Property Office titled "Mixed Micellar Delivery System and Method of Preparation."
The patent landscape for RNAi 'gene silencing' - including CSIRO's hairpin RNAi technology - has been significantly clarified following the resolution of several opposition and re-examination cases i
Nanogen has announced it was issued Patent No. 6,960,298, "Mesoporous permeation layers for use on active electronic matrix devices" by the U.S. Patent and Trademark Office. The '298 patent re
Date: Thursday, 10-Aug-2006
Rapid analysis and response in the very early stages of a pandemic or bioterrorism event can sharply limit its deadly impact.Surprisingly, a key early warning sensor for biologically- related illnesses may be the human body itself and Americans self-medicating with over the counter (OTC) treatments for "cold and flu" symptoms. Bracken Foster & Associates, LLC (d/b/a BioSentinel Solutions) has recently been granted a United States Patent for their groundbreaking efforts in the area of retail data biosurveillance. The company may now play a major role in America's pandemic influenza and bioterrorism preparedness efforts.
Current public health monitoring efforts focus largely on analyzing admissions activity at local Emergency Rooms and doctor offices. While these efforts are important they may not provide adequate early warning. Research confirms that consumers self-medicate with OTC products long before seeing a doctor. By the time enough data is accumulated through traditional means, the pandemic or bioterrorism event may have already taken hold. This delay means that critical time for detection and intervention is thereby lost, threatening thousands of lives.
"Trends in OTC product sales provide the very earliest indications of emerging threats to public health from viral or bacterial pathogens," said Todd Bracken, CEO BioSentinel Solutions. "OTC retailers, including pharmacies, grocery stores and mass merchandisers therefore play an important role in our country's preparedness efforts to combat pandemic influenza or bioterrorism."
Developed in cooperation with major retail chains, BioSentinel equips retailers to fill this important role while fully addressing and alleviating their concerns about the disclosure of otherwise sensitive product sales data and the potential overhead burden of program support.
The recent patent award confirms BioSentinel Solutions' position as the pioneering leader and now positions BioSentinel's superior methodology as the only choice for the collection and processing of retail sales data for biosurveillance purposes.
A division of Indianapolis-based Bracken Foster & Associates, LLC, BioSentinel Solutions is not a typical for-profit operation. The division was formed in the public interest in the wake of 9/11/01 by technology and product development expert Todd Bracken and others to address the lack of effective bio-event early warning in the event of pandemic influenza or bio-terrorist attack. Committed to cross-sector collaboration for inception, BioSentinel Solutions has grown to include a collaborative mix of not-for-profit organizations, public sector agencies, several prominent universities, and other private sector companies.
http://www.biosentinel.net/